目的 分析阜陽市人民醫(yī)院2019-2021年抑制胃酸分泌藥物使用情況,為促進(jìn)醫(yī)院抑制胃酸分泌藥物的合理使用及科學(xué)化管理提供參考。方法 對阜陽市人民醫(yī)院2019年1月-2021年12月抑制胃酸分泌藥物的銷售金額及構(gòu)成比、抑制胃酸分泌藥物的類別、藥品使用頻度(DDDs)、日均費(fèi)用(DDC)等進(jìn)行統(tǒng)計分析。結(jié)果 阜陽市人民醫(yī)院抑制胃酸分泌藥物有3類,2019-2021年抑制胃酸分泌藥物的銷售總金額及構(gòu)成比均逐年下降;質(zhì)子泵抑制劑銷售金額及構(gòu)成比逐年下降,而H₂受體阻斷劑的銷售金額及構(gòu)成比逐年升高,3類抑制胃酸分泌藥物中質(zhì)子泵抑制劑的銷售金額構(gòu)成比一直在90%左右。在藥品銷售金額排名中,埃索美拉唑腸溶膠囊、注射用艾司奧美拉唑排名相對比較穩(wěn)定一直處于前3名;艾普拉唑腸溶片、注射用法莫替丁銷售金額排名均呈上升趨勢,2021年艾普拉唑腸溶片消耗排名上升至第1位。2019-2021年DDDs排名前25位的抑制胃酸分泌藥品中,雷貝拉唑鈉腸溶膠囊連續(xù)2年DDDs排名第1位,艾普拉唑腸溶片、注射用法莫替丁和"4+7"抑酸藥物品種奧美拉唑腸溶膠囊使用頻度排名增幅顯著。2019-2021年,DDC超過100元的有4種,其中艾司奧美拉唑鈉粉針DDC值2019年為101.4元,2021年下降為71.66元,其他藥品的DDC值均低于100元。醫(yī)院內(nèi)僅1/3抑制胃酸分泌藥物的B/A接近于1。結(jié)論 阜陽市人民醫(yī)院抑制胃酸分泌藥物種類齊全,使用基本合理,但個別品種在藥物的選擇及使用方面存在不適宜現(xiàn)象,提示臨床醫(yī)師應(yīng)嚴(yán)格明確藥物適應(yīng)癥指導(dǎo)抑酸藥物的合理用藥,同時藥學(xué)部門需制定并開展抑酸藥的點(diǎn)評相關(guān)工作并針對用藥不合理之處積極與臨床醫(yī)生溝通,促進(jìn)抑酸藥物的合理使用。

Objective To analyze the use of anti-gastric acid secretion drugs in Fuyang People's Hospital from 2019 to 2021, and provide a reference for promoting the rational use and scientific management of anti-gastric acid secretion drugs in hospital.Methods Statistical analysis was performed on the sales amount and composition ratio of anti-gastric acid secretion drugs, the types of antigastric acid secretion drugs, the frequency of drug use (DDDs), and the average daily cost (DDC) in Fuyang People's Hospital from January 2019 to December 2021.Results There were 3 types of anti-gastric acid secretion drugs in Fuyang People's Hospital, and the total consumption sum and composition ratio of anti-gastric acid secretion drugs decreased year by year from 2019 to 2021. The consumption sum and composition ratio of proton pump inhibitors decreased year by year, while the consumption sum and composition ratio of H₂ receptor blockers increased, and the consumption sum ratio of proton pump inhibitors among the three types of anti-gastric acid secretion drugs had been above 90%. In the drug consumption sum ranking, Esomeprazole Enteric-soluble Capsules and Esomeprazole for injection ranked in the top 3, which was relatively stable. The consumption sum of Eprazole Enteric-coated Tablets and Motidine for injection showed an increasing trend, and the consumption sum of Eprazole Enteric-coated Tablets rose to the first place in 2021. Among the top 25 drugs for inhibiting gastric acid secretion in the list of DDDs from 2019 to 2021, Rabeprazole Sodium Enteric-soluble Capsules ranked first in DDDs for two consecutive years, Eprazole Enteric-coated Tablets, Motidine for injection and Omeprazole Enteric-soluble Capsules of "4 + 7" acid suppressive variety increased significantly in DDDs. From 2019 to 2021, DDC of 4 drugs exceeded 100 yuan, among which DDC value of Esomeprazole Sodium Powder was 101.4 yuan in 2019, and decreased to 71.66 yuan in 2021, and DDC value of other drugs were all below 100 yuan. There was only 1/3 of the drugs inhibiting gastric acid secretion had B/A close to 1 in Fuyang People's Hospital.Conclusion Fuyang People's Hospital has a complete range of drugs for suppressing gastric acid secretion, and the use is basically reasonable. But individual variety in selection and use of drugs is not suitable for phenomenon, clinical doctors should strictly guiding acid suppression drugs drug indications of rational drug use. Pharmaceutical sector need to formulate and carry out acid suppression drugs reviews related work for drug use unreasonable place actively communicate with clinicians, to promote rational use of acid suppressive drugs.

R975

國家自然科學(xué)基金資助項(xiàng)目(81703100)